



Universiteit  
Leiden  
The Netherlands

## **The replication machinery of *Clostridium difficile*: a potential target for novel antimicrobials**

Eijk, H.W. van

### **Citation**

Eijk, H. W. van. (2019, May 16). *The replication machinery of Clostridium difficile: a potential target for novel antimicrobials*. Retrieved from <https://hdl.handle.net/1887/73422>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/73422>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/73422> holds various files of this Leiden University dissertation.

**Author:** Eijk, H.W. van

**Title:** The replication machinery of *Clostridium difficile*: a potential target for novel antimicrobials

**Issue Date:** 2019-05-16

## The replication machinery of *Clostridium difficile*: a potential target for novel antimicrobials

1. The bacterial replisome can be used to develop both broad- and narrow-spectrum antimicrobials (this thesis, chapter 2).
2. Horizontal gene transfer between bacteria and its consequences are actively investigated, but intragenic translocation of genes and its (phenotypic) effect within bacteria such as *C. difficile* deserves equal attention (this thesis, chapter 3).
3. The mechanism of loading and activation of the replicative helicase of *C. difficile in vitro* is critically different from the Gram-positive model organism *B. subtilis* (this thesis, chapter 4 and 5).
4. Both direct and indirect effects of gene dosage shifts are likely to contribute to the transcriptional response of *C. difficile* to replication inhibition (this thesis, chapter 6).
5. Variation in stability of the helicase-primase interaction between bacterial species and species-specific cross-stimulation by helicase and primase suggests that molecules that inhibit this interaction may exert species-specific effects (this thesis, chapter 7).
6. Documenting provenance and whole genome sequencing should be common practice for laboratories using bacterial reference strains for their molecular work (Roberts AP and Smits WK. *Anaerobe* 2018).
7. Narrow-spectrum antimicrobials, such as fidaxomicin, are useful to prevent or treat opportunistic infections such as CDI, that are associated with dysbiosis of the microbiome (Louie *et al.* *Clin Infect Dis.* 2012, Ajami *et al.* *Antimicrob. Agents Chemother.* 2018).
8. The importance of gene order is reflected in the strong conservation of the *oriC*-proximal co-localization of important growth factors involved in replication, transcription and translation (Slager J and Veening JW. *Trends Microbiol.* 2016).
9. Guidelines and statistical practice should abandon the sharp division between superiority and non-inferiority in clinical trials and be more closely aligned to the clinical and public health questions that motivate the trial (adapted from Dunn *et al.* *Trials* 2018, Gerding *et al.* *Lancet Infect Dis.* 2019).
10. Effective automation in clinical microbiology does not mean making the system do what is done without automation. It may require a revolutionary different approach. (Adapted from Burckhardt I. *Bioengineering* 2018).
11. Obtaining a PhD – like travel – in the younger sort, is a part of education; in the elder, a part of experience (Adapted from Francis Bacon. *Essays of Counsels, Civill and Morall*, 1625).